Trial reportEuropean journal of clinical pharmacology2010
Effect of dose timing in relation to food intake on systemic exposure to blonanserin.
Trial report in European journal of clinical pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- High-Fat Meal Increase Blonanserin Bioavailability 5-Fold in Chinese Healthy Subjects.Drug design, development and therapy · 2025Trial
- Evaluating the pharmacokinetics and safety of blonanserin tablets and LonasenFrontiers in pharmacology · 2024Article
- Novel therapies for nausea and vomiting in advanced illness and supportive cancer care.Palliative care and social practice · 2024Review
- Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report.Neuropsychopharmacology reports · 2021Article
- Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO.The international journal of neuropsychopharmacology · 2018Article
- Lipids in the Stomach - Implications for the Evaluation of Food Effects on Oral Drug Absorption.Pharmaceutical research · 2018Review
- Effects of food and grapefruit juice on single-dose pharmacokinetics of blonanserin in healthy Chinese subjects.European journal of clinical pharmacology · 2018Article
- The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses.Clinical drug investigation · 2014Article
- Simple and sensitive analysis of blonanserin and blonanserin C in human plasma by liquid chromatography tandem mass spectrometry and its application.Journal of analytical methods in chemistry · 2014Article
- Newer antipsychotics and upcoming molecules for schizophrenia.European journal of clinical pharmacology · 2013Review
- Profile of blonanserin for the treatment of schizophrenia.Neuropsychiatric disease and treatment · 2013Article
- Blonanserin's interesting food-effect observations: is lymphatic transport involved?European journal of clinical pharmacology · 2011Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBlonanserin is a novel potent dopamine D(2) and serotonin 5-HT(2) antagonist for treating schizophrenia. The aim of this study was to investigate prandial effects on systemic exposure to blonanserin in healthy volunteers, with particular attention paid to the effect of dose timing relative to meal intake.
methodsVolunteers received a single 2-mg oral dose of blonanserin under the following conditions: fasting, 30 min before eating a standard meal; or 30 min or 2 or 4 h after eating the meal. Plasma concentrations of blonanserin were measured using validated high-performance liquid chromatography coupled with tandem mass spectrometry.
resultsRatios and 90% confidence intervals of the geometric means compared with the fasting condition indicated that the maximum concentrations of blonanserin (C(max)) significantly increased with dosing 30 min before meal intake, and 30 min and 2 and 4 h after meal intake, yielding by 330%, 239%, 272%, and 138%, respectively. The truncated area under the concentration-time curve (AUC(last)) also increased by 386%, 201%, 256%, and 155%, respectively. There was no difference in values of the time to reach maximum concentration between the fasting and the four fed states.
conclusionsFood intake increased the systemic exposure to blonanserin for all time intervals investigated in this study. The marked effect of food on the bioavailability of blonanserin should be taken into account in its dosing schedules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.